Bcl-2 interacts with the inositol 1,4,5-trisphosphate receptor (InsP 3 R) and thus prevents InsP 3 -induced Ca 2+ elevation that induces apoptosis. Here we report that Bcl-2 binds dopamine-and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), a protein kinase A (PKA)-activated and calcineurin (CaN)-deactivated inhibitor of protein phosphatase 1 (PP1). Bcl-2 docks DARPP-32 and CaN in a complex on the InsP 3 R, creating a negative feedback loop that prevents exaggerated Ca 2+ release by decreasing PKA-mediated InsP 3 R phosphorylation. T-cell activation increases PKA activity, phosphorylating both the InsP 3 R and DARPP-32. Phosphorylated DARPP-32 inhibits PP1, enhancing InsP 3 R phosphorylation and Ca 2+ release. Elevated Ca 2+ activates CaN, which dephosphorylates DARPP-32 to dampen Ca 2+ release by eliminating PP1 inhibition to enable it to dephosphorylate the InsP 3 R. Knocking down either Bcl-2 or DARPP-32 abrogates this feedback mechanism, resulting in increased Ca 2+ elevation and apoptosis. This feedback mechanism appears to be exploited by high levels of Bcl-2 in chronic lymphocytic leukemia cells, repressing B-cell receptor-induced Ca 2+ elevation and apoptosis.
calcium | lymphocyte | cancer | signaling | signal transduction P eriodic elevations of intracellular Ca 2+ serve as second messengers regulating mitochondrial metabolism, cell cycle entry, and cell survival (1, 2) . Ca 2+ signals are generated when inositol 1,4,5-trisphosphate receptors (InsP 3 Rs) open in response to InsP 3 , thus transferring Ca 2+ from the endoplasmic reticulum into the cytoplasm and mitochondria. InsP 3 R-mediated Ca 2+ release is highly regulated, as excessive Ca 2+ release causes cellular dysfunction and death (3) . A number of proteins bind to InsP 3 Rs and regulate channel opening, thus preventing excessive Ca 2+ release (4) . Among these is the antiapoptotic protein B-cell lymphoma-2 (Bcl-2) (5).
The Bcl-2 homology domain 4 (BH4) domain of Bcl-2 mediates its interaction with InsP 3 Rs (6, 7) . This domain also binds the Ca 2+ /calmodulin-activated serine/threonine (Thr) protein phosphatase calcineurin (CaN) (8) . The BH4 domain binds within the regulatory and coupling domain of the InsP 3 R, located between the InsP 3 binding site near the N terminus and the channel domain near the C terminus (6) . Protein kinase A (PKA) phosphorylates serine (Ser) 1589 and Ser1755 within this domain, increasing InsP 3 -mediated channel opening and Ca 2+ release (9) . Bcl-2 is reported to regulate InsP 3 R phosphorylation at Ser1755 and to thereby govern InsP 3 R-mediated Ca 2+ release in murine embryonic fibroblasts, although the mechanism is not yet identified (10) .
Bcl-2 plays an important role in regulating T-cell development and selection, processes that involve Ca 2+ signaling and apoptosis regulation (11, 12) . A 20-amino acid peptide (InsP 3 Rderived peptide, or IDP) corresponding to the Bcl-2 binding site on the InsP 3 R inhibits Bcl-2-InsP 3 R interaction, thus eliminating Bcl-2's control over InsP 3 R-mediated Ca 2+ elevation (6, 7) . This peptide induces marked Ca 2+ elevation and Ca 2+ -mediated apoptosis in primary chronic lymphocytic leukemia (CLL) cells and in B-cell lymphoma lines, indicating that Bcl-2-InsP 3 R interaction contributes to the apoptosis-resistance characteristic of these lymphoid malignancies (13, 14) .
Here we report that Bcl-2 interacts with dopamine-and cAMPregulated phosphoprotein of 32 kDa (DARPP-32), a potent inhibitor of protein phosphatase 1 (PP1) that is activated by PKA-mediated phosphorylation at Thr 34 and deactivated by CaN-mediated dephosphorylation at this site (15) . Our findings indicate that Bcl-2 docks DARPP-32 and CaN on the InsP 3 R, creating a negative feedback loop that responds to InsP 3 R-mediated Ca 2+ release by inhibiting InsP 3 R phosphorylation at Ser1755, thereby preventing excessive Ca 2+ elevation capable of inducing cell death. Our findings implicate this Bcl-2-CaN-DARPP-32 feedback mechanism in regulating Ser1755 phosphorylation and apoptosis in primary human CLL cells.
Results
Bcl-2 Regulates InsP 3 R-1 Ser1755 Phosphorylation. T-cell lines are used in the present work, as in previous studies (8, 13, 16) . Jurkat is a human CD4 + T-cell line that expresses readily detectable levels of Bcl-2 (Fig. 1A) . The murine WEHI7.2 T-cell line is CD4 + /CD8 + -positive and thus corresponds to an early developmental stage in which Bcl-2 levels are low. These cells are referred to as "Lo Bcl-2" cells to distinguish them from Bcl-2 overexpressing WEHI7.2 cells, referred to as "Hi Bcl-2" cells ( Fig. 1A) . Bcl-2 levels are undetectable in the S49 murine T-cell line (Fig. 1A) . This line is useful because of two available mutants deficient in PKA activity: one lacking Gα s (Cyc − , historical naming) and the other lacking functional PKA (PKA − ) (17) .
Significance
The B-cell lymphoma-2 (Bcl-2) protein binds to the inositol 1,4,5-trisphosphate receptor (InsP 3 R), a ubiquitous intracellular Ca 2+ channel, thereby promoting cell survival by preventing excessive Ca 2+ elevation. We report here that this mechanism involves Bcl-2 interaction with the Ca 2+ -activated protein phosphatase calcineurin (CaN) and dopamine-and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), a CaN-regulated inhibitor of protein phosphatase 1. Our findings indicate that this complex constitutes a rapid negative feedback mechanism that is activated by Ca 2+ elevation and decreases InsP 3 R phosphorylation, thus inhibiting InsP 3 R-mediated Ca 2+ release. We posit that Bcl-2-overexpressing cancer cells may exploit this mechanism to inhibit apoptosis. In WEHI7.2 cells, Bcl-2 overexpression inhibits anti-CD3-induced Ca 2+ elevation, as previously reported (6, 7, 18, 19) (Fig. 1 B  and C) . Before adding anti-CD3, basal InsP 3 R-1 phosphorylation at Ser1755 in Hi Bcl-2 WEHI7.2 cells is equal to or greater than phosphorylation at this site in Lo Bcl-2 WEHI7.2 cells. On average, the ratio of phosphorylated (P)-Ser1755 InsP 3 R-1 levels in Hi Bcl-2 to Lo Bcl-2 cells, normalized to actin, is 1.3 ± 0.3 (n = 7; P = 0.16). InsP 3 R-1 P-Ser1755 levels increase after anti-CD3 treatment in Lo Bcl-2 WEHI7.2 cells but decrease in Hi Bcl-2 WEHI7.2 cells (Fig. 1 D  and E) . The increase in Ser1755 phosphorylation in Lo Bcl-2 WEHI7.2 cells is inhibited by the PKA inhibitor H89 (N- [2- 
as is phosphorylation of cAMP response element-binding protein (CREB), a known PKA target (Fig. S1A ). In addition, anti-CD3-mediated T cell receptor (TCR) activation increases InsP 3 R-1 Ser1755 phosphorylation in S49 cells, but not in Cyc − and PKA − S49 cells (Fig. S1C) . These findings are consistent with evidence that TCR activation increases the activity of PKA (20) and indicate that anti-CD3 induced phosphorylation of InsP 3 R-1 at Ser1755 is PKAmediated. Moreover, the findings indicate that InsP 3 R Ser1755 phosphorylation contributes to the increase in cytoplasmic Ca 2+ concentration induced by anti-CD3 treatment, as H89 treatment or PKA deficiency are associated with a marked decrease in anti-CD3-induced Ca 2+ elevation ( Fig. S1 B and D) . In summary, anti-CD3-induced TCR activation increases PKAmediated phosphorylation of Ser1755 in InsP 3 R-1, and this phosphorylation enhances anti-CD3-induced Ca 2+ elevation. Bcl-2, in contrast, is associated with a decline in Ser1755 phosphorylation induced by anti-CD3 antibody treatment, and this decline correlates with Bcl-2-mediated inhibition of anti-CD3-induced Ca 2+ elevation.
Bcl-2-Mediated Inhibition of Ser1755 Phosphorylation Involves Both
CaN and PP1. Because the BH4 domain of Bcl-2 binds CaN, we investigated a possible role of CaN in mediating the Bcl-2-associated decline in Ser1755 phosphorylation. Intracellular Ca 2+ chelation by BAPTA-AM [1,2-Bis(2-aminophenoxy)ethane-N,N,N′, N′-tetraacetic acid tetrakis(acetoxymethyl ester)] reverses the inhibitory effect of Bcl-2 on anti-CD3-induced elevation of InsP 3 R-1 P-Ser1755 ( Fig. 2A ). In addition, the CaN inhibitor tacrolimus (FK506) (21) increases InsP 3 R-1 P-Ser1755 levels ( Fig. 2 B and C) and reverses the inhibitory effect of Bcl-2 on anti-CD3-induced Ca 2+ elevation ( Fig. 2 D and E). These findings implicate CaN in the mechanism by which Bcl-2 decreases InsP 3 R-1 P-Ser1755 after TCR activation. However, PKA-mediated protein phosphorylation is typically regulated by PP1 (22) , and the effects of CaN on the InsP 3 R are predicted to be indirect and secondary to the action of PP1 (23) . Therefore, in vitro phosphatase assays were used to clarify the respective roles of CaN and PP1 in regulating Ser1755 phosphorylation on InsP 3 R-1. WEHI7.2 cells were pretreated with forskolin to increase InsP 3 R-1 P-Ser1755 levels, and then InsP 3 R1s were immunoprecipitated from cell lysates. Immune-captured InsP 3 R-1 was incubated with purified PP1 or PP2A enzymes in a phosphatase assay buffer (24) . Under these conditions, recombinant PP1 and PP2A retain their substrate specificities (24) . PP1, but not PP2A, causes a dose-dependent decrease of InsP 3 R-1 P-Ser1755 (Fig. 2F ). Consistent with this conclusion, 2 μM okadaic acid, a concentration that inhibits PP1 (22, 25, 26) , reverses the inhibitory effect of Bcl-2 on anti-CD3-induced elevation of P-Ser1755 InsP 3 R-1 and Ca 2+ (Fig. S2 ). Moreover, an in vitro phosphatase assay was used to assess the effect of CaN on InsP 3 R-1 P-Ser1755 (21) . Incubation with purified CaN does not alter the phosphorylation of immune-captured InsP 3 R-1, regardless of the presence of Ca 2+ (Fig. 2G ). CaN shifts the mobility of a typical CaN target, NFATc2, ensuring that CaN is active in the assay system (Fig. 2G) .
These findings indicate a direct role for PP1 and an indirect role for CaN in Bcl-2-mediated regulation of InsP 3 R-1 phosphorylation at Ser1755, suggesting potential involvement of DARPP-32 in regulating InsP 3 R phosphorylation at Ser1755.
DARPP-32 and CaN
Interact with Bcl-2 on the InsP 3 R-1 and Regulate Ca 2+ Elevation and Cell Survival. DARPP-32 is detected at equal levels in both Lo Bcl-2 and Hi Bcl-2 WEHI7.2 cells, along with InsP 3 R-1, PKA, PP1, and CaN, the levels of which are similar regardless of differing Bcl-2 levels (Fig. 3A) . Bcl-2 immunoprecipitation from Lo Bcl-2 and Hi Bcl-2 cells pulls down both DARPP-32 and CaN, whereas these proteins are not pulled down by control IgG antibody (Fig. 3B ). Bcl-2-DARPP-32 interaction is confirmed in the reciprocal experiment, where DARPP-32 is immunoprecipitated, pulling down both InsP 3 R-1 and Bcl-2 (Fig. 3C) . DARPP-32 also coimmunoprecipitates with ΔBH4-Bcl-2, a previously described Bcl-2 mutant that lacks the BH4 domain and neither interacts with the InsP 3 R-1 or CaN nor regulates TCR-induced Ca 2+ elevation (6, 16) (Fig. 3D ). These findings indicate that DARPP-32 interaction with Bcl-2 by itself is insufficient to regulate Ca 2+ and that CaN interaction with the BH4 domain of Bcl-2 and Bcl-2 interaction with the InsP 3 R are required to form a functional Bcl-2-CaN-DARPP-32 complex. This conclusion is substantiated by experiments in WEHI7.2 cells expressing Bcl-2 6,7mut, a previously described dicodon mutant in which arginine at position 6 and serine at position 7 in the BH4 domain of Bcl-2 are replaced by glycine (6) . Immunoprecipitation of this mutant form of Bcl-2 pulls down DARPP-32 (Fig. 3D ). Because this Bcl-2 mutant neither interacts with InsP 3 Rs nor inhibits anti-CD3-induced Ca 2+ elevation (6), the coimmunoprecipitation of DARPP-32 with Bcl-2 6,7mut confirms that the Bcl-2-DARPP-32 complex must be localized to the InsP 3 R to function in regulating InsP 3 R-mediated Ca 2+ release. Consistent with these observations, TCR activation induces PKA-mediated DARPP-32 phosphorylation at Thr34 in cells expressing low levels of Bcl-2 or Bcl-2 6,7mut, whereas in cells expressing high levels of wild-type Bcl-2, basal P-Thr34 levels are already elevated and decline after TCR activation (Fig. 3E) . Reversal of Bcl-2's Action by Knocking Down Bcl-2 or DARPP-32. The Bcl-2 level in Jurkat T-cells is sufficient to attenuate anti-CD3-induced Ca 2+ elevation (6). Here we find that siRNA-mediated Bcl-2 knockdown in Jurkat cells reverses the inhibitory effect of Bcl-2 on InsP 3 R Ser1755 phosphorylation (Fig. 4 A and B) . Thus, an anti-CD3-induced elevation of InsP 3 R Ser1755 phosphorylation is observed in cells in which Bcl-2 is knocked down, but not in control cells in which Bcl-2 is present and increased after anti-CD3 treatment. As reported previously (6), knocking down Bcl-2 results in increased Ca 2+ elevation in response to anti-CD3 (Fig.  4C) . Knocking down DARPP-32 ( Fig. 4D ) also increases InsP 3 R Ser1755 phosphorylation (Fig. 4 E and F) . Moreover, DARPP-32 knockdown increases anti-CD3-induced Ca 2+ elevation (Fig.  4G) and apoptosis (Fig. 4H ) in Jurkat cells, suggesting a role for this feedback mechanism in preserving cell survival after TCR activation.
Regulation of P-Ser1755 InsP 3 R-1 Involving Bcl-2 and DARPP-32 in CLL Cells. To investigate the potential relevance of these findings in pathological conditions, we investigated InsP 3 R phosphorylation in CLL, a common form of leukemia invariably associated with elevated Bcl-2 levels, combined with tonic B-cell receptor signaling expected to generate InsP 3 R-mediated Ca 2+ elevation (27) . In recent studies, we found that treating primary human CLL cells with the peptide TAT-IDP DD/AA , which inhibits Bcl-2-InsP 3 R interaction, induces Ca 2+ elevation and, consequently, apoptosis (13). Here we detect the expression of DARPP-32 in primary human CLL cells (Fig. S3A ) and find that treating these cells with TAT-IDP DD/AA increases P-Ser1755 InsP 3 R-1 levels (Fig. S3 B and C), followed by Ca 2+ elevation (Fig. S2D ). These findings indicate that peptide-mediated disruption of Bcl-2-InsP 3 R interaction overcomes Bcl-2-imposed repression of P-Ser1755 InsP 3 R-1 levels and InsP 3 R-1-mediated Ca 2+ release. These findings suggest that CLL cells exploit the Bcl-2-CaN-DARPP-32-mediated negative feedback mechanism to prevent Ca 2+ elevation and cell death.
Discussion
The findings reported here indicate that Bcl-2 provides a molecular platform bringing CaN and DARPP-32 together on InsP 3 R-1, producing a rapid feedback mechanism that senses InsP 3 R-1-mediated Ca 2+ release and responds by inhibiting PKA-mediated InsP 3 R-1 phosphorylation at Ser1755 (Fig. 5) . In a two-step process, CaN initiates the feedback process by sensing Ca 2+ elevation and responds by dephosphorylating DARPP-32, thereby eliminating its inhibition of PP1. The Ca 2+ elevation that triggers CaN activation in this step, we posit, is localized at the mouth of the InsP 3 R, where CaN is positioned in close proximity to Bcl-2. Thus, this Ca 2+ signal is not detected by the global 
measurement of intracellular Ca
2+ used in this study. In the second step, PP1 dephosphorylates P-Ser1755 InsP 3 R-1, decreasing the InsP 3 R-mediated Ca 2+ release that is readily detected by global Ca 2+ measurements (e.g., Fig. 1B ). In creating a negative feedback loop, Bcl-2 exploits the properties of CaN and DARPP-32 by targeting them to InsP 3 R-1, where they respond rapidly to the Ca 2+ exiting the InsP 3 R-1 channel (Fig. 5) . The requirement for Bcl-2 to assemble CaN and DARPP-32 in close proximity to InsP 3 R-1, whether all four proteins are in the same Bcl-2 complex or in close proximity in distinct pools of Bcl-2, is supported experimentally by evidence that the feedback mechanism is not operational when Bcl-2 is substituted with mutant forms of Bcl-2 that do not interact with InsP 3 R-1. Moreover, as PKA phosphorylates Ser1588 with similar effects on InsP 3 R-1-mediated Ca 2+ release (9), it is likely that the Bcl-2-mediated feedback mechanism would also regulate phosphorylation at this site, contributing to the effects of Bcl-2 on InsP 3 R-mediated Ca 2+ release. In summarizing the findings in Fig. 5 , we emphasize the dynamic changes in P-Ser1755-InsP 3 R-1 and P-Thr34-DARPP-32 that constitute the rapid feedback mechanism that takes place after TCR activation. For simplicity, this diagram does not show an increased basal phosphorylation of Ser1755-InsP3R-1 and Thr34-DARPP-32, although it is detected in certain experiments (Figs. 1D and 3E ). Because PKA associates with InsP 3 R-1 (4), we hypothesize that an elevation of basal P-Ser1755 InsP 3 R-1 in cells with elevated Bcl-2, when observed, is secondary to constitutive TCR activity mediating basal PKA activity that increases P-Thr34-DARPP-32 levels, in turn inhibiting PP1 and thus raising the basal level of P-Ser1755 InsP 3 R-1.
DARPP-32 has been investigated extensively in the brain, where it localizes to regions enriched in dopaminergic nerve terminals (15) . The possibility that DARPP-32 may mediate effects of CaN on InsP 3 R-1-induced Ca 2+ release had been suggested previously (22, 23) . Moreover, Tang and colleagues (22) discovered a direct association between PP1 and InsP 3 R-1 and established that the association with PP1 facilitates dephosphorylation of PKA-phosphorylated InsP 3 R-1. These investigators established the role of AKAP9, a multifunctional PKA anchoring protein, in docking PKA and PP1 to InsP 3 R-1 (28) and in experiments with medium spiny neurons from DARPP-32 knock-out mice, demonstrated a regulatory role of DARPP-32 in dopamine-induced Ca 2+ oscillations (29) . Although these results advance our understanding of crosstalk between cAMP and InsP 3 -mediated Ca 2+ signaling pathways in the brain, much less is known about the role of DARPP-32 in peripheral tissues, including lymphocytes, although DARPP-32 has been shown to increase the phosphorylation and activity of various ion channels (30) . The findings reported here are an indication of an interaction between Bcl-2 and DARPP-32 and of a role of this interaction in regulating Ca 2+ signaling and cell survival. Our findings indicate that the negative feedback mechanism conferred through Bcl-2 interaction with DARPP-32 and CaN contributes to the antiapoptotic function of the Bcl-2 protein. By regulating PKA-mediated InsP 3 R phosphorylation at Ser1755, the Bcl-2-CaN-DARPP-32 complex sets a threshold level that Ca 2+ cannot exceed, thereby preventing Ca
2+
-induced cell death. Knocking down either Bcl-2 or DARPP-32 abrogates this protective mechanism, elevating Ser1755 phosphorylation and thus increasing Ca 2+ elevation after TCR activation, leading to loss of cell viability. Moreover, IDP DD/AA -mediated inhibition of Bcl-2-InsP 3 R interaction also abrogates this feedback mechanism, leading to cell death in primary human CLL cells. Thus, the Bcl-2-CaN-DARPP-32-mediated feedback mechanism may be essential to block proapoptotic Ca 2+ signals and thereby prolong survival of CLL cells and possibly other Bcl-2-positive malignancies. Although the present report focuses on Ca 2+ signaling in lymphocytes, one can speculate that the Bcl-2-CaN-DARPP-32 feedback mechanism may also function in neuronal cells and that defects in this pathway may contribute to neuropsychiatric illnesses. TCR stimulation by anti-CD3 increases activities of both phospholipase C (PLC), to increase InsP 3 synthesis, and adenylyl cyclase, to increase cAMP. The latter activates PKA, which phosphorylates Thr34-DARPP-32. PKA also phosphorylates Ser1755-InsP 3 R-1, and this phosphorylation step is enhanced by the PP1 inhibitory activity of P-Thr34-DARPP-32. (C) InsP 3 activates InsP 3 R-1 channel opening, which is enhanced by its phosphorylation at Ser1755. Ca 2+ released from the endoplasmic reticulum activates CaN, which dephosphorylates P-Thr34-DARPP-32, alleviating inhibition of PP1 and initiating the feedback process. (D) Continuing the feedback process, PP1 dephosphorylates P-Ser1755, decreasing InsP 3 R-1 channel opening and thus reducing Ca 2+ release, accompanied by the inactivation of InsP 3 either through hydrolysis to InsP 2 or phosphorylation to InsP 4 .
Bcl-2 plays an important role in the development and survival of neuronal cells (31 (34, 35) . Moreover, the mechanism of action of mood stabilizers effective in treating this disorder involves, at least in part, elevation of Bcl-2 and stabilization of Ca 2+ signaling (36) . DARPP-32, in contrast, regulates many pathways in the central nervous system coupled with long-term plasticity and control of behavior (15) . Altered DARPP-32 function has been implicated in the pathogenesis of schizophrenia (15) , and DARPP-32 expression is deficient in leukocytes from patients with schizophrenia and bipolar disorder (37) . Therefore, future studies are needed to investigate a potential functional link between unregulated Ca 2+ signaling in these disorders and potential alterations in a Bcl-2-CaN-DARPP-32 feedback pathway required to prevent excessive Ca 2+ signaling.
Materials and Methods
Reagents, primary cells, and cell lines have been described previously (6, 13) . Also described are methods of peptide synthesis, immunoblotting and immunoprecipitation (6), T-cell stimulation by anti-CD3 antibodies and Ca 2+ imaging (6), RNA interference (6) , and in vitro phosphatase assays (24) . Details of these methods and statistical analysis are in SI Materials and Methods.
